Prof. Stéphane Depil is onco-hematologist at Léon Bérard Cancer Center, group leader at Cancer Research Center of Lyon, adjunct Professor at University Claude Bernard Lyon 1, France, and Visiting Professor at King’s College London, founder and Chief Executive Officer of ErVaccine Technologies.
He is a board-certified physician in hematology and has over 15 years of experience in oncology development, both in academic centers and pharmaceutical companies. He obtained a PhD in immunology at Institut de Biologie de Lille after working on a project of cancer vaccination.
He worked at Servier Research Institute for 8 years in a variety of roles, including Director of Oncology Research and Development, where he managed 20 oncology programs. He also directly supervised the evaluation of over 100 licensing opportunities. He is author of more than 100 articles and abstracts and co-inventor of 10 patents.
Between 2014 and 2016, he served as Chief Executive Officer at NETRIS Pharma and between 2017 and 2019, was Senior Vice President Research & Development at Cellectis.
In 2019, he founded ErVaccine Technologies and became Chief Executive Officer of the company.